Chewy vs. MercadoLibre: Steady Results vs. Rapid Revenue Growth

MercadoLibre generated $10.2 billion of Q2 2026 revenue versus Chewy's $3.3 billion, extending a widening revenue gap after MercadoLibre's sales rose 50% year over year. MercadoLibre's Q2 net income fell 11% as it reinvested in e-commerce and fintech, while Chewy delivered 7% revenue growth and a 29% increase in net income. MercadoLibre's faster growth and AI-search rollout support its longer-term case, though its 48x P/E exceeds Chewy's 28x and carries greater execution risk.

Analysis

The relevant divergence is not revenue scale but incremental monetization: MELI is deliberately converting marketplace liquidity into higher-take-rate fintech, credit and logistics penetration, while CHWY’s mature core category limits top-line optionality. MELI’s near-term earnings deleveraging should be evaluated against credit-loss provisions, funding costs and fulfillment investment rather than treated as simple margin erosion. If those inputs stabilize while engagement improves from search changes, the market can re-rate MELI on normalized 2027 earnings power over the next 6-18 months.

CHWY’s improved earnings conversion is attractive only if it reflects durable gross-margin gains and recurring Autoship/customer economics, not reduced promotional intensity or deferred growth spending. The veterinary expansion raises customer lifetime value but is likely a multi-quarter margin drag through clinic ramp, staffing and occupancy; it also places CHWY in more direct competition with privately held veterinary consolidators and specialty retailers. Food-safety recalls among third-party brands create a modest substitution opportunity for CHWY’s owned brands, but also elevate fulfillment, returns and reputational risk if product traceability is weak.

The cleaner relative expression is MELI long/CHWY short, but entry should wait for evidence that MELI’s investment cycle is not masking a deteriorating credit book. Consensus may be underestimating MELI’s ability to use payments and lending data to reinforce marketplace conversion, while over-rewarding CHWY’s current margin improvement despite low structural revenue growth. Conversely, MELI’s premium multiple is vulnerable to any acceleration in delinquency, FX volatility or Brazil/Mexico funding costs, making this unsuitable as an unhedged momentum chase.

Key Decisions for Investors

• Initiate a 6-12 month market-neutral long MELI / short CHWY pair after the next earnings releases, sized 1.0x/0.7x beta-adjusted. Target 15-25% relative return if MELI demonstrates stable credit metrics and CHWY guides to continued low-single-digit revenue growth; exit if MELI’s consolidated credit-loss/provision trend worsens materially for two quarters or CHWY reaccelerates revenue above 10% with sustained margin expansion.
• For MELI, add only on post-results volatility if management confirms that incremental logistics and fintech investment is producing transaction-frequency or merchant-acquisition gains. A 10-15% drawdown tied solely to investment-led EBIT pressure is a buyable entry; avoid adding if the selloff follows weaker loan vintage performance, rising funding costs, or adverse FX translation.
• Maintain CHWY as a watch-list short rather than a standalone position ahead of veterinary-business disclosures. Trigger a short if clinic investment causes EBITDA-margin guidance to compress without corresponding active-customer or Autoship growth; cover on evidence of material private-label mix expansion or veterinary revenue scaling faster than fixed costs.
• Do not infer read-through from NFLX or NVDA: neither has an operative exposure to the retail/fintech mechanism here. Monitor Latin American consumer-credit conditions, local policy rates and MELI’s delinquency cohorts as the primary 1-3 month catalysts.